Savings and support

Could the TIBSOVO® Copay Program Help Lower your Copay?

If your insurance is commercial (a health insurance plan you have through an employer or through a private plan) and you are eligible, you may pay as little as $0 per prescription for TIBSOVO through the Copay Program.

Who is eligible?*

  • Patients who reside in the US, US territories, or Puerto Rico
  • Patients who have a plan through an employer or have a private plan, and are paying a portion of the cost

*Not valid for patients whose prescription claims are reimbursed in whole or in part by any state or federal government program, including Medicaid, Medicare, Medigap, Department of Defense (DOD), Veterans Affairs (VA), TRICARE.


TIBSOVO offers additional programs to help patients access their medication depending on their situation

Are insurance delays keeping you from starting treatment?

Learn about the QuickStart Program

Waiting on insurance? The TIBSOVO® QuickStart Program can help during a delay

If your insurance company takes more than 5 business days to approve your treatment, our QuickStart Program is here to help. If you're eligible, we will send you a 30-day supply of your medicine so you do not have to wait to start treatment.*

*As prescribed by your healthcare provider.

Who is eligible?
  • Patients who reside in the U.S., U.S. territories, or Puerto Rico
  • Patients who are government insured, have a plan through an employer, or have a private plan
How to enroll

Fill out the appropriate sections of the TIBSOVO Enrollment Form and then work with your healthcare provider to complete it. Your healthcare provider will fax your completed form to the ServierONE Patient Support Program at 1-877-770-7102.

Need help accessing your medication during a temporary coverage gap?

Learn about the Bridge Program

The Bridge Program helps you get treatment during a short-term insurance coverage gap

Changing insurance? Waiting on new insurance? The Bridge Program is designed to provide a one-time, 1-month supply of TIBSOVO to a qualified patient experiencing a short-term lapse in coverage.

This program gives you access to TIBSOVO while your insurance issues are being resolved.

Who is eligible?*
  • Patients who reside in the U.S., U.S. territories, or Puerto Rico
  • Patients who have a plan through an employer or have a private plan

*Not valid for patients whose prescription claims are reimbursed in whole or in part by any state or federal government program, including Medicaid, Medicare, Medigap, Department of Defense (DOD), Veterans Affairs (VA), TRICARE.

How to enroll

Fill out the appropriate sections of the TIBSOVO Enrollment Form and then work with your healthcare provider to complete it. Your healthcare provider will fax your completed form to the ServierONE Patient Support Program at 1-877-770-7102.


ServierONE patient support

Find additional support and guidance to help you pay for TIBSOVO

Personalized support

Dedicated Patient Experience Managers can help you navigate insurance, financial support, and access to your treatment.

Government insurance support

Financial assistance resources for people with Medicare, Medicaid, TRICARE, VA, DOD, and other government healthcare programs are available.

Uninsured & underinsured support

People who are uninsured or experience gaps in coverage may be eligible for programs that help with access to treatment.

Email USPatientServices@servier.com or call 1‑800‑813‑5905 (Monday-Friday, 8 AM to 8 PM ET) to contact a Patient Services representative directly.

Please see ServierONE.com for full Terms and Conditions.

Downloadable resources

Tools that can help

The downloadable materials below may be helpful to you and your healthcare team.

TIBSOVO® (ivosidenib tablets) CCA Patient Brochure.

TIBSOVO CCA Patient Brochure

Your guide to IDH1‑targeted CCA treatmentIDH1 stands for isocitrate dehydrogenase-1. In healthy cells, IDH1 plays an important role in normal chemical reactions. When IDH1 is altered due to a genetic mutation, it may promote the development of certain types of cancers, including cholangiocarcinoma. with TIBSOVO.

TIBSOVO® (ivosidenib tablets) Medication Guide.

Medication Guide

Important information to know about taking TIBSOVO.

Patient advocacy

Patient advocacy, support, and assistancea

There are many patient organizations and online support groups for people living with CCA. To learn more about CCA, to find clinical trials, or to connect with other patients, the list of groups below and other organizations may be useful resources.

American Cancer Society®

1-800-227-2345

cancer.org

Cancer Support Community

1-888-793-9355

cancersupportcommunity.org

Cholangiocarcinoma Foundation®

1-385-218-3013

cholangiocarcinoma.org

HealthWell Foundation®

1-800-675-8416

healthwellfoundation.org

Patient Advocate Foundation

1-800-532-5274

patientadvocate.org

aThese are independent resources. Financial support eligibility is determined by the individual foundation. Servier Pharmaceuticals is not affiliated with these organizations.

Servier provides charitable funding to many patient organizations providing support and education to patients and families. The above list may not include all patient organizations available to patients and families.

 

What is TIBSOVO?

TIBSOVO is a prescription medicine used to treat adults with an isocitrate dehydrogenase-1 (IDH1) mutation with bile duct cancer (cholangiocarcinoma) that has spread and who have already received previous treatment(s).

Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.

 

IMPORTANT SAFETY INFORMATION

TIBSOVO may cause serious side effects, including:

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before and during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint
  • Guillain-Barré Syndrome has happened in people treated with TIBSOVO. Your healthcare provider will monitor you for nervous system problems and will permanently stop your treatment with TIBSOVO if you develop Guillain-Barré syndrome. Tell your healthcare provider right away if you develop any signs or symptoms of Guillain-Barré syndrome, including:
  • weakness or tingling feeling in your legs, arms, or upper body
  • numbness and pain on one side or both sides of your body
  • any changes in your ability to see, touch, hear, or taste
  • burning or prickling sensation
  • difficulty breathing

The most common side effects of TIBSOVO in adults with cholangiocarcinoma include:

  • fatigue
  • nausea
  • abdominal pain
  • diarrhea
  • cough
  • decreased appetite
  • fluid and swelling in your stomach area
  • vomiting
  • hemoglobin decreased (anemia)
  • rash
  • changes in liver function tests

Your healthcare provider will do blood tests before you start and during treatment with TIBSOVO. Your healthcare provider may decrease, temporarily hold, or permanently stop your treatment with TIBSOVO if you develop certain side effects.

TIBSOVO may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of TIBSOVO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking TIBSOVO, tell your healthcare provider about all of your medical conditions, including if you:

  • have any heart problems, including a condition called long QT syndrome
  • have problems with abnormal electrolytes, such as sodium, potassium, calcium, or magnesium levels
  • have nervous system problems
  • have problems with your kidneys or are on dialysis
  • have any liver disorders, including cirrhosis
  • are pregnant or plan to become pregnant. TIBSOVO can cause harm to your unborn baby. You should avoid becoming pregnant during treatment with TIBSOVO. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with TIBSOVO
  • are breastfeeding or plan to breastfeed. It is not known if TIBSOVO passes into your breast milk. Do not breastfeed during your treatment with TIBSOVO and for 1 month after your last dose of TIBSOVO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take hormonal contraceptives. TIBSOVO may affect how hormonal contraceptives work and may cause them to not work as well.

Please see Full Prescribing Information, including Medication Guide.

Last update: September 2026

Information on this website is reviewed through established medical, legal, and regulatory processes to support accurate, balanced, and label-consistent communication about TIBSOVO.

 

What is TIBSOVO?

TIBSOVO is a prescription medicine used to treat adults with an isocitrate dehydrogenase-1 (IDH1) mutation with bile duct cancer (cholangiocarcinoma) that has spread and who have already received previous treatment(s).

Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

TIBSOVO may cause serious side effects, including:

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before and during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint

IMPORTANT SAFETY INFORMATION